Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2027

Conditions
PTSD
Interventions
DRUG

5 mL of 0.5% preservative-free bupivacaine

IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.

Trial Locations (1)

K1Z 7K4

The Royal Ottawa Mental Health Centre, Ottawa

Sponsors
All Listed Sponsors
collaborator

Ottawa Hospital Research Institute

OTHER

lead

The Royal's Institute of Mental Health Research

OTHER